Physician

Pediatrics

Andrew Tershakovec works in the field of Pediatrics. He researched medicine at University of Miami Miller School of Medicine. University of Miami Miller School of Medicine is ranked 45 in research and 0 in primary care medicine Andrew Tershakovec is also published. He has 91 publications published. The lastest publication: "Psychosocial factors in nutrition education for hypercholesterolemic children.'

Publications

---

• Changing characteristics of statin-related cIMT trials from 1988 to 2006.
• Time-related trends in variability of cIMT changes in statin trials.
• Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
• Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
• Combination therapy in dyslipidemia: Where are we now?
• LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy.
• Attainment of ldl-cholesterol goals is suboptimal with rosuvastatin monotherapy in us patients at high cardiovascular risk.
• Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE...
• Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for co...
• Intestinal sterol transporters and cholesterol absorption inhibition.
• Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels...
• The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients.
• Response by Sex to Statin plus Ezetimibe or Statin Monotherapy: A Pooled Analysis from 22,231 Hyperlipidemic Patients.
• Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
• Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in sub...
• Sustained Hypophosphatemic Effect of Once-Daily Niacin/Laropiprant in Dyslipidemic CKD Stage 3 Patients.
• Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients.
• Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart d...
• Lipid lowering for secondary prevention of cardiovascular disease in older adults.
• Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/...
• Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
• Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hyp...
• Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic synd...
• Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly Z...
• Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
• Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic ...
• Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and p...
• Letter by Tershakovec et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-c...
• Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patie...
• Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
• Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to ba...
• Progress and controversies: treating obesity and insulin resistance in the context of hypertension.
• Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary h...
• Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of...
• Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high ris...
• Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
• Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia.
• Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
• A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.
• Ezetimibe: cholesterol lowering and beyond.
• Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of t...
• Correlation of measures of pain, function, and overall response: results pooled from two identical studies of etoricoxib in chronic low back pain.
• Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
• Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia.
• Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes.
• Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.
• A double-blind randomized controlled trial of rofecoxib and multidose oxycodone/acetaminophen in dental impaction pain.
• Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
• Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.
• Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
• Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, pla...
• Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
• Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
• Calcium and dairy intake and measures of obesity in hyper- and normocholesterolemic children.
• A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain.
• Psychological considerations in pediatric weight management.
• Prediction equations for resting energy expenditure in overweight and normal-weight black and white children.
• Obesity during childhood and adolescence augments bone mass and bone dimensions.
• HIV-related lipodystrophy and related factors.
• Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
• Acupuncture for the treatment of obesity: a review of the evidence.
• Ethnicity, insurance type, and follow-up in a pediatric weight management program.
• Body composition and metabolic factors in obese children and adolescents.
• Persistent hypercholesterolemia is associated with the development of obesity among girls: the Bogalusa Heart Study.
• Age, sex, ethnicity, body composition, and resting energy expenditure of obese African American and white children and adolescents.
• Diet quality of young children who received nutrition education promoting lower dietary fat.
• Early risk factors for increased adiposity: a cohort study of African American subjects followed from birth to young adulthood.
• Resting energy expenditure and prediction equations in young children with failure to thrive.
• Nutrition interventions in childhood for the prevention of chronic diseases in adulthood.
• Insurance reimbursement for the treatment of obesity in children.
• Psychosocial factors in nutrition education for hypercholesterolemic children.
• Growth of hypercholesterolemic children completing physician-initiated low-fat dietary intervention.
• Age-related changes in cardiovascular disease risk factors of hypercholesterolemic children.
• Long-term growth and development in children after home parental nutrition.
• One-year follow-up of nutrition education for hypercholesterolemic children.
• The cost-effectiveness of alternative methods of nutrition education for hypercholesterolemic children.
• The effect of changes in dietary fat on the food group and nutrient intake of 4- to 10-year-old children.
• Effects of family history of heart disease, apolipoprotein E phenotype, and lipoprotein(a) on the response of children's plasma lipids to change in dietary lipids.
• The influence of age and relative weight on the presentation of familial combined hyperlipidemia in childhood.
• The cost of implementation of the Clinical Laboratory Improvement Amendments of 1988--the example of pediatric office-based cholesterol screening.
• Reduction of elevated LDL-cholesterol levels of 4- to 10-year-old children through home-based dietary education.
• Obesity, school performance and behaviour of black, urban elementary school children.
• The effect of blood lead on blood pressure in children.
• Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
• Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-loweri...
• Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monother...
• Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subcl...
• Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein choleste...
• Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular dis...
• Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.

Doctors Specialties

---

• Pediatrics

Accepted Insurances

---

Education

---

• New York Presbyterian Hospital - Columbia Campus
• University of Miami Miller School of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Elgie R. McLaughlin, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard C. Lapat, MD This Doctor is OpenDoctor Recommended.
	Dr. Mary J. Teter, DO
	Dr. Michael D. Levin, MD
	Dr. Karen M. Kaplan, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog